Global Secondary Progressive Multiple Sclerosis Drug Market Size By Type (Inebilizumab, GLX-1112), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Secondary Progressive Multiple Sclerosis (SPMS) Drug Market was valued at USD 4.1 billion in 2023 and is projected to reach USD 8.6 billion by 2031, expanding at a CAGR of 9.4% during the forecast period (2023–2031). The increasing prevalence of SPMS, a debilitating form of multiple sclerosis, along with ongoing advancements in disease-modifying therapies, is fueling market growth. Rising patient awareness, growing access to treatment options, and the emergence of novel drug formulations are creating robust demand for SPMS drugs globally. The market is further supported by strategic partnerships, clinical trials, and regulatory support aimed at addressing unmet therapeutic needs.

Drivers:

1. Rising Global Prevalence of Multiple Sclerosis (MS):

SPMS typically develops from relapsing-remitting MS (RRMS), and with over 2.8 million people globally living with MS, the demand for SPMS-specific therapies continues to rise. Increasing diagnosis rates and enhanced clinical understanding are key contributors.

2. Advancements in Drug Development:

New-generation SPMS therapies like siponimod and ocrelizumab demonstrate improved efficacy in slowing disease progression. Biopharmaceutical companies are investing heavily in R&D pipelines focused on neurodegenerative and autoimmune disorders, leading to the introduction of novel and targeted treatments.

3. Regulatory Incentives and Orphan Drug Designation:

SPMS treatments often receive orphan drug status, fast-track approvals, and government funding due to their focus on a rare, high-burden disease. These incentives accelerate product launches and market expansion.

Restraints:

1. High Cost of Treatment:

SPMS therapies, particularly biologics and novel oral agents, can be prohibitively expensive. Limited insurance coverage and high out-of-pocket expenses in low-income regions hinder treatment adoption.

2. Limited Treatment Efficacy for Late-Stage SPMS:

Many current therapies have reduced effectiveness in non-relapsing SPMS patients. This limits their clinical utility, especially in individuals with long-standing disease progression and significant disability.

Opportunity:

1. Emerging Therapies and Biomarker-Based Treatment Approaches:

Ongoing clinical trials and biomarker-driven drug development promise greater personalization of SPMS therapy. Biotech startups and pharmaceutical giants are exploring CNS-penetrant drugs and remyelination agents.

2. Market Expansion in Developing Regions:

Growing healthcare infrastructure in countries like Brazil, India, and China opens new avenues for SPMS drug manufacturers. Increased government focus on neurological diseases and broader access to neurologists are contributing to market penetration.

Market by System Type Insights:

The Oral Drug segment held the largest market share in 2023, driven by the convenience, improved patient compliance, and growing adoption of oral disease-modifying therapies such as siponimod. These drugs offer a favorable safety profile and ease of administration compared to injectable formulations.

However, the Injectable Biologic segment is projected to witness the fastest growth rate over the forecast period, with ongoing trials focusing on monoclonal antibodies and B-cell-depleting therapies such as ocrelizumab gaining traction.

Market by End-use Insights:

In 2023, the Hospitals and Specialty Clinics segment accounted for the largest revenue share due to the availability of advanced diagnostic and treatment facilities. The presence of specialized neurologists and integrated care pathways supports patient adherence and treatment efficacy.

The Homecare and Ambulatory Settings segment is expected to grow significantly, fueled by patient preference for self-administered therapies and remote monitoring tools that enhance long-term disease management outside traditional clinical settings.

Market by Regional Insights:

North America led the market in 2023, accounting for over 40% of the global revenue, supported by high MS prevalence, strong reimbursement frameworks, and the presence of major pharmaceutical players. The region also benefits from active clinical research and favorable regulatory pathways.

Europe held the second-largest share, with rising awareness, improved healthcare access, and supportive government policies contributing to market expansion.

Asia-Pacific is projected to witness the highest growth during the forecast period. Increased healthcare investments, rising diagnosis rates, and a growing patient population are enhancing the region’s market potential.

Competitive Scenario:

Key players in the Global SPMS Drug Market include:

Novartis AG

Roche Holding AG

Sanofi S.A.

Biogen Inc.

Teva Pharmaceutical Industries Ltd.

Bristol Myers Squibb

Johnson & Johnson

Merck KGaA

TG Therapeutics Inc.

Immunic Therapeutics

These companies are pursuing strategies such as new product launches, strategic acquisitions, and clinical research collaborations to strengthen their market position. Noteworthy developments include:

2023: Novartis expanded access to siponimod (Mayzent) across new geographies with regulatory approvals in Asia-Pacific and Latin America.

2024: Roche initiated a Phase III trial of ocrelizumab for progressive MS patients without relapse activity.

2025: Biogen collaborated with academic institutions to develop digital biomarkers for SPMS disease progression.

Scope of Work – Global Secondary Progressive Multiple Sclerosis Drug Market

Key Market Developments:

May 2023: FDA expanded the label of siponimod to include SPMS patients with active and non-active disease.

Aug 2024: Sanofi launched a digital therapy companion app for SPMS patients undergoing cladribine therapy.

Mar 2025: Teva announced clinical trial results for a novel oral agent showing promise in slowing disability progression in SPMS.

FAQs:

1) What is the current market size of the Global Secondary Progressive Multiple Sclerosis Drug Market?

The market size was valued at USD 4.1 billion in 2023.

2) What is the major growth driver of the Global Secondary Progressive Multiple Sclerosis Drug Market?

The key growth driver is the rising global prevalence of MS and the development of targeted therapies for SPMS.

3) Which is the largest region during the forecast period in the Global Secondary Progressive Multiple Sclerosis Drug Market?

North America is the largest region due to robust healthcare infrastructure and favorable reimbursement policies.

4) Which segment accounted for the largest market share in the Global Secondary Progressive Multiple Sclerosis Drug Market?

The Oral Drug segment held the largest market share in 2023.

5) Who are the key market players in the Global Secondary Progressive Multiple Sclerosis Drug Market?

Major players include Novartis AG, Roche Holding AG, Biogen Inc., Sanofi S.A., and Teva Pharmaceutical Industries Ltd.